chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Her arm is also really sore; chills; headache; low grade fever of 99.6-100.2; achy from head to toe/ generally achy all over; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Her arm is also really sore), CHILLS (chills), HEADACHE (headache), PYREXIA (low grade fever of 99.6-100.2) and MYALGIA (achy from head to toe/ generally achy all over) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Breast cancer (Patient had breast cancer years ago on her left side, so she cannot have anything in her left arm). Concurrent medical conditions included Thyroid disorder NOS and Anxiety. Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO) for Anxiety, LEVOTHYROXINE SODIUM (SYNTHROID) for Thyroid disorder NOS.    On 29-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Her arm is also really sore), CHILLS (chills), HEADACHE (headache), PYREXIA (low grade fever of 99.6-100.2) and MYALGIA (achy from head to toe/ generally achy all over). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at a dose of 2 tablets and PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Her arm is also really sore) had not resolved and CHILLS (chills), HEADACHE (headache), PYREXIA (low grade fever of 99.6-100.2) and MYALGIA (achy from head to toe/ generally achy all over) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.6-100.2 (High) low grade fever of 99.6-100.2.         Patient took 2 tablets of Advil, that helped her kind off a little to take the edge off, and she waited a few hours to take Tylenol, but that did not help. She mentioned experiencing similar reactions with the 2nd dose
Low grade fever onset 24 hours after injection , duration 36 hours.  Spike of 101.5 13 hours after onset.
Patient reports that they have had pain at the injection site starting the day after the vaccination but that the pain continues to persist as of 11-18-2020 despite attempts to treat it with OTC Tylenol, Ibuprofen as well as icing the area.
Experience slight Shortness of breath; Heart palpitations; Twitching in his right eye; Teeth grinding at night; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Experience slight Shortness of breath), BLEPHAROSPASM (Twitching in his right eye), BRUXISM (Teeth grinding at night) and PALPITATIONS (Heart palpitations) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Apr-2021, the patient experienced BLEPHAROSPASM (Twitching in his right eye) and BRUXISM (Teeth grinding at night). On an unknown date, the patient experienced DYSPNOEA (Experience slight Shortness of breath) and PALPITATIONS (Heart palpitations). At the time of the report, DYSPNOEA (Experience slight Shortness of breath), BLEPHAROSPASM (Twitching in his right eye), BRUXISM (Teeth grinding at night) and PALPITATIONS (Heart palpitations) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient reported that he had the eye twitch before when he drinks any caffeine. No relevant concomitant medications were reported. No treatment information was reported..
Service member currently at hospital for comprehensive evaluation for reactive arthritis that developed initially in Nov 06. Discussed history of symptom development in relation to vaccine receipt. Pt remembers that initial symptoms started in Nov 06 and that he had inflammation in the bilateral knees in Dec 06. History also reveals that pt seemed to flare after receipt of the anthrax #1 and smallpox vaccinations on 5 Apr 07. Pt has severe disease and is currently on enbrel, methotrexate, mobic and vicodin to try to control pain and inflammation. Has permanent joint damage in it wrist in spite of ongoing treatment with immune modulators.
Information has been received from a registered nurse referring to seven unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On unspecified dates, between 28-JUN-2016 and 05-JUL-2016, the patients were vaccinated with improperly stored PROQUAD (recombinant human albumin (rHA); lot # L046510 with expiry date 19-MAY-2017; dose and frequency were not reported), subcutaneously. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
pt states about 3 hours after IMZ she got fever, chills, red arm as could be expected (lasting about 18 hours), but also respiratory. She said no stomach symptom but respiratory much worse than when she had covid and her arm  looks sunburned and peeling.
Had all the shots, had shingles in face and hair/ Suspeced vaccination failure; Shingles in face and hair; That pain from hairline near eye/ equivalent to sticking your finger in light socket; Stress; Immune system disorder; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Had all the shots, had shingles in face and hair/ Suspeced vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: Shingles in face and hair), pain (Verbatim: That pain from hairline near eye/ equivalent to sticking your finger in light socket), stress (Verbatim: Stress) and immune system disorder (Verbatim: Immune system disorder). The outcome of the vaccination failure was unknown and the outcome of the shingles and pain were not resolved and the outcome of the stress and immune system disorder were not reported.   It was unknown if the reporter considered the vaccination failure, shingles, pain, stress and immune system disorder to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure, shingles, pain, stress and immune system disorder to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 31-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that he or she received all doses of Shingles vaccine. The patient experienced shingles and they stated that his or her immune system and stress made it just right to take shingles on his or her face and hair. The patient stated that it was almost 3 months and still have shingles. The patient went to the eye physician and later saw neurologist. The patient reported that it was worst he or she ever experienced and he or she was told that it was equivalent to sticking your finger in light socket that pain was from hairline near the eye. The physician stated that it could be take 6 months. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible as no contact details were available.
accidentally given typhim vi instead of ipol with no reported adverse event; vaccine was also administered subcutaneously instead of intramuscularly as it was thought they are administering ipol with no reported adverse event; Initial information received on 26-Apr-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 9 months old male patient who was accidentally given typhim vi instead of ipol with and vaccine was also administered subcutaneously instead of intramuscularly as it was thought they are administering ipol with no reported adverse event while receiving vaccine typhoid vi polysaccharide vaccine [Typhim VI].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (Daptacel), hib vaccine conj (tet tox) (Acthib), pneumococcal vaccine conj 13v (crm197) (Prevnar 13) and influenza vaccine inact split 3v (Fluarix) for Prophylactic vaccination.  On 25-Apr-2022, the patient received 0.5ml once dose of suspect typhoid vi polysaccharide vaccine (strength, formulation was unknown, lot T1E142M and expiry date: 03-Sep-2022) via subcutaneous route in unknown administration site for Immunization.  On 25-Apr-2022, (Latency: same day) the patient was accidentally given typhim vi instead of ipol and administered subcutaneously instead of intramuscularly as it was thought they are administering ipol with no reported adverse event (wrong product administered, incorrect route of product administration).   Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events   Outcome: Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
just a little pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: PAIN (non-serious), outcome "recovered", described as "just a little pain".  Additional information: The patient stated that the first shot did not cause the type of pain, just a little pain but it went away after 2 to 3 days. The patient stated that she was wondering if there was any way she could get a smaller shot. She stated that she would be willing to complete a report but she was having trouble hearing with the connection. She agreed to be transferred back to complete the report after she spoke with Medical Information when she had a better connection.   The lot number for [BNT162B2], was not provided and will be requested during follow up.
The child ran a fever of 100-103 from 3/21/2017 to 3/24/2017 and was given baby motrin to bring it down, which helped. On 3/24/2017, a mild spotted rash appeared over the child's entire body and lasted until 3/29/2017.
Onset of swelling redness, warmth & pain of right upper arm this AM (~12-16 hours after DTaP was given in right arm). Increased over the course of the day and today. Comfort measures only recommended- hot compress, Tylenol, Motrin
Pt received 1st dose Pfizer vaccine 3/11/2021, as did other members of her household.  She developed fever, arthralgia, myalgia. Fever resolved in 2 days; arthralgia and myalgia lasted much longer, resolving slowly. States she was largely back to her baseline -- which because of her chronic conditions is pain 3-6/10 -- after about 15 days.  Had concerns about getting second dose of vaccine, but received it as scheduled. Developed fever, myalgia, arthralgia again 12 hours after receipt of second dose.  Fever resolved in four days, and myalgia slowly improved, but joint pain has been getting worse.  Now with pain in back, shoulders, knees, hips, wrists knuckles of her hands and feet.  Reporting daily pain 6-9 out of ten.                                            Evaluated by Sports Medicine 4/14 and 4/19, and by primary care physician (filing this report) 5/4.  Reports of pain are consistent and worsening.
Swelling, pain, erythema, increased warmth at injection site. Dizziness, fever 102, myalgias.
PT has subjective symptoms of numbness and tingling in lower feet that comes and goes (approx several minutes to hours)  up to 4-5 times  week. Started a month after last pzifer shot for covid. Pt request to have vaers request due to concern about htis. Pt has not had any trauma or falls. Not taking medication for numbness or tingling. Not on any medications prior. Has resolved afteR 6 weeks.  PT is concerned for neuropathy being caused from shot.
Initial report receive from a health care provider on 4/6/2006. A 17 year old male patient, with no pre existing medical conditions, had received a right deltoid injection of Menactra, Lot number U1808AA, on 1/16/2006. He had also received an injection of Tetanus Diphtheria vaccine, manufacturer not reported. lot number not reported, route and site of administration not reported, on 1/13/2006. One day following the Menactra vaccination and four day following the Tetanus diphtheria vaccination, the patient experience severe headaches, stiff neck, fever, nausea. Per the reporter, the event required hospitalization, and two weeks following discharge, the patient still had not returned to school. Relevant testing included a CT scan, chest X ray and spinal tap although results were not provided. The reporter indicated that the responsible physician noted on the VAERS report is not the patients personal physician ant that she did not have contact information for the personal physician or additional information concerning this case.
Have had hives spontaneously (different places on body at random times) since 10 days after dose
I received second shot of Moderna at the same location on 02/14/2021.  Approximately April 14, I experienced tinnitus and it has continued until this date.  I also had a hearing test and was told by the audiologist that I had a profound hearing loss.  Up to this point, I have never had an ear infection and had no problem with hearing.   I am reporting this event in case there are others and you may find the vaccine causes sudden hearing loss and/or tinnitus.
This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient) reported that a female patient of unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiration date not provided), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. It was reported that patient received 1st dose of Covid vaccine. Right after her husband had tested positive for Covid virus. Patient did not take test. Said had all symptoms. Such as fever, loss of smell, taste, diarrhea and being nauseous on unspecified dates. Was sick for whole month. Patient wondering if she could not get 2nd dose of Covid vaccine or what to do as she wanted to return work. The outcome of the events was unknown. Information on the lot/batch number has been requested.
Status epilepticus requiring multiple antiepileptics, IVIG, high-dose steroids, plasmapheresis. Afebrile. The patient is still in the ICU as of 8/1/2022.
Patient received booster of Moderna (025ml) on 10/25/21. According to website specific lot number has an exp of of 10/24/21. LOT 026C21A. I reached out to manufacturer for guidance if patient should receive an additional booster dose -still waiting on contact from manufacturer.
thrombophlebitis and thrombus of her right greater saph vein (superficial vein thrombus)
This is a literature report. The authors reported 4 reports, this is the 3rd of 4 reports and refers to case 2. A previously healthy 21-month-old boy presented to the emergency department with a 1-day history of fever to 103 F, emesis, cough, and lethargy. Rapid influenza testing was positive for influenza A, and oseltamivir was started. History was notable for day care attendance and multiple sick contacts. He was full immunized, including PCV13. The next morning, he had a brief seizure with eye deviation and generalized convulsions, and became obtunded. Simultaneously, blood culture grew gram-positive cocci in pairs and chains. He returned to the emergency department, where he had right-sided weakness, posturing, rightward eye deviation, and meningismus as well as further seizures requiring lorazepam and fosphenytoin. Laboratory testing were performed. Ceftriaxone and vancomycin were started at meningitic dosing. Cerebrospinal fluid grew S pneumonia serotype 15B, a non vaccine serotype. The large number of pneumococcal serotypes, and the possibility for even less invasive serotypes such as 15B to produce invasive disease as in patient 2, also provide support for alternative vaccination strategies that are not serotype-specific. MRI performed showed multifocal infarction. Imaging progressed to multifocal vasculitis, new ischemic strokes, and CSVT. Steroid therapy with dexamethasone 0.6 mg/kg per day was started on hospital (HD) 6 and continued through HD 19. Aspirin 81 mg (5 mg/kg per day) was started on HD 6 for secondary stroke prevention. Clinical worsening prompted the initiation of steroid therapy in accordance with published recommendations for the treatment of central nervous system vasculitis, although the evidence supporting specific treatments of vasculitis especially secondary to infection is limited. The patient remained seizure free after admission on phenytoin and then switched to levetiracetam. He was intermittently febrile for 7 days. He received 21 days of ceftriaxone and 5 days of oseltamivir; vancomycin was stopped after 48 hours when speciation and susceptibility results returned. Hydrocephalus developed with an acute decompression on HD 30 with apnea, desaturation, and emesis, for which an endoscopic ventricular drain was placed. He later underwent endoscopic third ventriculostomy with choroid plexus cauterization on HD 35. He spent a total of 42 days in the hospital. He passed a hearing test before discharge. Five months after discharge, at 27 months of age, the patient was meeting developmental milestones with a normal neurologic examination. There was no seizure recurrence and repeat EEG was normal, so levetiracetam was discontinued. This case of vaccinated child with pneumococcal meningitis due to non-PCV13 serotypes highlight its spectrum of cerebrovascular disease and morbidity. Pfizer is marketing authorization holder of Pneumococcal 13-val conj Vac in the report's country. This may be a duplicate report if another marketing authorization of Pneumococcal 13-val conj vac has submitted the same report to the regulatory authorities.
pt recv vax 25PAR97 & felt hot @ 11PM;230AM 26APR97 no fever;sl fever next day;APAP given;fever inc had sz & taken to ER by amb t103 in ER:given APAP & Advil in ER dx febrile sz;BP 100/palp, P180, R28;eyes rolled back & shaking,given 02
Initial information received on 21 January 2009 from a health care professional. A 27 year old female patient with a history of tonsillectomy received ADACEL (lot number not reported) intramuscularly on 19 January 2009. The next morning, on 20 January 2009 the patient complained of total body urticaria, periorbital edema, and swelling of her ears. The patient was evaluated by her physician (date not provided). The patient was treated with BENADRYL and DEPOMEDROL. the patient's symptoms persisted and the patient was not recovered at the time of the report. List of Documents held by Sender: none.
Injection site and muscle soreness, expected, had that last time. This was second shot. Hit with upset stomach, shivering, naseau that did not occur after first shot. Read on site can take a few days so will take pain reliever and rest.
Patient developed moderate edema/erythema and itching of her entire right arm after PNEUMOVAX on 8/21/14.
Fever, shakes, severe body aches and sharp pains throughout my body. Nausea and vomiting and constant use of the bathroom. Dizziness, and severe migraine, fatigue and trouble breathing that lasted 2+ hours.
This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number was not reported), via an unspecified route of administration on an unspecified date as dose 1, single dose and via an unspecified route of administration on an unspecified date (Lot number was not reported) as dose 2, single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unknown date, the patient had a suppressed immune system. It was reported that patient had a suppressed immune system and had received the first two vaccination shots for COVID-19 but was interested in participating in a trial for a booster if one is available. Outcome of the event was unknown. Information about Lot/batch number has been requested.
pt got a moderna vaccine instead of pfizer. mom signed up for moderna and was not caught at window.
OSTEOARTHRITIS; UPPER EXTREMITY DYSFUNCTION; This spontaneous report received from a patient concerned a 60 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: moderate to severe rheumatoid arthritis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Non-company suspect drugs included: upadacitinib (oral, batch number: 1159488 expiry: UNKNOWN, form of admin was not reported) dose, frequency, and therapy dates were not reported for moderate to severe rheumatoid arthritis. No concomitant medications were reported. On an unspecified date, the patient experienced osteoarthritis, and upper extremity dysfunction. Treatment medications (dates unspecified) included: methotrexate, and celecoxib. The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and action taken with upadacitinib was not reported. The patient had not recovered from osteoarthritis, and upper extremity dysfunction. This report was non-serious.  This case, involving the same patient is linked to 20220853756 and 20220853753.
Patient experienced muscle aches. The muscle aches started the day that the vaccine was administered. The muscle aches gradually got worse each day. She is still experiencing them today and feels like she was hit by a freight train.
Dizziness, unfocused, high blood pressure 170/100 for weeks; now on lisinopril 10mg.